Routine conflict of interest disclosure by preclinical lecturers and medical students' attitudes toward the pharmaceutical and device industries.

his disclosures, adding government and private funding sources, and indicating “a misunderstanding of the requirements for reporting of conflicts of interest.” However, a check of other online published COI statements shows that Reynolds failed to disclose additional pharmaceutical conflicts from the 36-month period prior to the submission of the work, which are required disclosures according to the guidelines of the International Committee of Medical Journal Editors. In an article from January 2010, his COI stated: “Dr Reynolds receives research support . . . from GlaxoSmithKline, Forest Laboratories, Pfizer, Lilly, Bristol-Myers Squibb, and Wyeth.” In an article from 2009, Reynolds’ disclosure included “ . . . recipient of grant support in the form of medication supplies for investigator initiated trials from GlaxoSmithKline, Forest Pharmaceuticals, Inc. Laboratories, Pfizer Inc., US Pharmaceuticals Group, Eli Lilly and Company, and BristolMyers Squibb Company.” In another example, Reynolds coauthored an article in which the funding statement read that the work was “supported by a grant from and developed in theory with Cephalon Inc.” Because several of the entities Reynolds omits from his COI disclosures (eg, GlaxoSmithKline, US Pharmaceuticals Group, and Cephalon) could be perceived to benefit from the substance of the article on preventing depression, it seems appropriate for Reynolds to disclose these relationships.